Melbourne-based Medical Developments International (ASX:MVP) has announced that Penthrox, its fast-onset, non-opioid analgesic for pain relief by self-administration, has been launched in Italy.
According to CEO John Sharman, “We are delighted to finally launch Penthrox in the important European market of Italy. There has been a number of clinical studies completed in preparation for the launch of Penthrox in Italy.
"In particular, a study of 272 trauma patients in 15 Italian emergency units (MEDITA), showed that Penthrox was SUPERIOR to Standard of Care, including Opioids, for adult trauma pain patients in Italy.”
He continued, “The launch of Penthrox in Italy will trigger another milestone payment from our partner Mundipharma of US$2million which is expected during 2020. Penthrox is now well placed to develop into a leading trauma pain medication in Italy and throughout Europe.”
Maya Marescotti of Mundipharma in Europe said, “We are delighted to have launched Penthrox in Italy, to help provide fast and effective relief for adult patients experiencing trauma pain. We see this inhaled analgesic as an important medication for trauma patients here and throughout Europe and we look forward to our continued collaboration with MDI.”